SB 273005

structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Edema (Dropsy) 01/01/2001 - "When SB 273005 was administered prophylactically to AIA rats twice per day, it inhibited paw edema at doses of 10, 30, and 60 mg/kg, by 40%, 50%, and 52%, respectively. "
2.	Arthritis (Polyarthritis) 01/01/2001 - "Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis." 01/01/2001 - "To evaluate the effects of SB 273005, a potent, orally active nonpeptide antagonist of the integrin avbeta3 vitronectin receptor, on joint integrity in rats with adjuvant-induced arthritis (AIA). "